Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.
Chronic Lymphocytic Leukemia
DRUG: IDEC-152
Determine a recommended Phase II dose for the treatment of patients with relapsed or refractory CLL, 48 months|Characterize the safety profile of IDEC-152, 48 months
Evaluate the pharmacokinetics and pharmacodynamics of IDEC-152 in patients with relapsed or refractory CLL, 48 months|Evaluate the efficacy of IDEC-152 in patients with relapsed or refractory CLL, 48 months
To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.